Form 4: ProMIS Neurosciences Director Patrick Kirwin Granted Stock Options

ProMIS Neurosciences Inc. director Patrick D. Kirwin was granted 20,000 stock options with an exercise price of $0.50, vesting by June 12, 2026.

Summary

• Patrick D. Kirwin, a director of ProMIS Neurosciences Inc. (PMN), was granted 20,000 stock options.
• The options have an exercise price of $0.50 per share.
• The options will vest in full on the earlier of the first anniversary of the grant date (June 12, 2025) or June 12, 2026, subject to continued service on the Board.
• The options expire on June 12, 2035.
• Following this transaction, Mr. Kirwin beneficially owns 20,000 derivative securities (options).

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step for corporate governance, aligning the director's interests with shareholder value. It is a routine compensation event and does not indicate specific operational or financial performance.

Positives

• The grant of stock options to Director Patrick D. Kirwin aligns his interests with those of shareholders, incentivizing long-term performance and retention.

Future Outlook

The options are designed to incentivize the director's continued service and align his interests with the company's long-term performance, with vesting tied to future service.

Industry Context

The granting of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, used to attract, retain, and incentivize key personnel by aligning their financial interests with the company's long-term success and shareholder value creation.

Comparison to Industry Standards

• The grant of stock options to a director is a standard compensation mechanism widely employed across publicly traded companies, particularly in growth-oriented sectors like biotechnology. While specific comparable companies or projects are not detailed in this filing, such grants are typically benchmarked against peer group compensation practices to ensure competitiveness and appropriate incentive structures.

Stakeholder Impact

• Shareholders: The grant of stock options aims to align the director's long-term interests with shareholder value creation, potentially leading to improved governance and strategic decisions.

Next Steps

• Continued service on the Board by Patrick D. Kirwin for the options to vest.

Key Dates

Keywords

ProMIS Neurosciences, PMN, stock options, director compensation, SEC Form 4, insider transaction, equity grant